证券代码：000710 证券简称：贝瑞基因 公告编号：2023-044 成都市贝瑞和康基因技术股份有限公司 关于控股股东及其一致行动人终止协议转让部分股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"、"本公司"） 于近日收到公司控股股东高扬先生及其一致行动人侯颖女士的通知，高扬先生及 侯颖女士与黄麒玮及国信证券股份有限公司协商并达成一致意见，于近日签署了 《股份转让协议之解除协议》，现将相关事项公告如下： 三、本次协议转让终止对公司的影响 本次协议转让终止事项不会影响上市公司目前的日常经营状况和财务状况， 不会对公司治理结构及持续经营产生不利影响，亦不存在损害公司及全体股东利 益的情形。 四、其他说明 本次协议转让终止不存在违反《证券法》、《上市公司收购管理办法》、《深 圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施细则》及 相关承诺、部门规章、规范性文件等相关规定的情形。 一、本次协议转让的基本情况 公司控股股东高扬先生及其一致行动人侯颖女士于 2023 年 4 月 14 日与黄 ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 高扬先生持有公司股份37,610,572股（占公司总股本比例为10.6063%），为 公司控股股东，侯颖女士持有公司股份20,205,661股（占公司总股本比例为 5.6981%），为控股股东的一致行动人。高扬先生、侯颖女士因质押到期将被国 信证券股份有限公司通过集中竞价的方式分别减持本公司股份不超过7,092,117股 （占公司总股本比例不超过2 %）。 证券代码：000710 证券简称：贝瑞基因 公告编号：2023-045 成都市贝瑞和康基因技术股份有限公司 关于控股股东及其一致行动人被动减持股份的预披露公告 股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"或"本公司"） 于近日收到控股股东高扬先生及其一致行动人侯颖女士通知，其因个人质押到 期，所持有的公司部分股份拟被进行违约处置。现将有关情况公告如下： | 股东名称 | 持股数量（股） | 占总股本比例 | 质押股份数量（股） | 占公司总股本的比例 | | --- | -- ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥560,696,060.91, a decrease of 17.58% compared to ¥680,298,823.07 in the same period last year[23]. - The net loss attributable to shareholders for the first half of 2023 was ¥95,107,757.01, representing a significant increase in loss of 410.92% from a loss of ¥18,614,878.56 in the previous year[23]. - The net cash flow from operating activities was -¥6,079,577.63, a decline of 145.31% compared to a positive cash flow of ¥13,416,869.47 in the same period last year[23]. - The basic and diluted earnings per share for the first half of 2023 were both -¥0.2690, a decrease of 348.33% from -¥0.0600 in the previous year[23]. - The total assets at the end of the reporting period were ¥3,152,427,038.59, down 1.51% from ¥3,200,862,871.74 at the end of the previous year[23]. - The net assets attributable to shareholders decreased by 4.01%, from ¥2,301,386,725.87 to ¥2,209,030,127.85[23]. - The company reported a total non-operating loss of approximately -13.24 million CNY in the first half of 2023[30]. - The company achieved total revenue of CNY 560.70 million, a decrease of 17.58% compared to the same period last year[49]. - Net profit was CNY -93.78 million, with a net profit attributable to shareholders of CNY -95.11 million, a decrease of 410.92% year-on-year[49]. - Revenue from medical testing services was CNY 223.79 million, down 16.38% year-on-year[50]. - Revenue from reagent sales was CNY 212.39 million, a decrease of 12.40% compared to the previous year[50]. - Revenue from equipment sales was CNY 24.14 million, down 52.09% year-on-year[50]. - The company reported a net profit of -¥35,184.6 million for its subsidiary Beijing Berry Genomics, indicating a loss during the reporting period[73]. - The company reported a total comprehensive income of ¥2,751,356.97 for the current period[156]. - The total comprehensive income for the first half of 2023 was -34,374,308.67 CNY, compared to -38,990,384.33 CNY in the first half of 2022[149]. Business Operations - The company focuses on high-throughput sequencing technology for genetic testing services and related equipment and reagent sales[31]. - The main business areas include reproductive health, genetic disease testing, tumor detection, and scientific services[31]. - The company offers non-invasive prenatal genetic testing (NIPT) with the "Bebian" and "Bebian Plus" tests, covering 100 types of chromosomal diseases[32]. - The "Kenuoan" test provides chromosome copy number variation detection, analyzing over 100 kb of CNVs[33]. - The company has developed a comprehensive newborn screening program, "Beixinan," covering 407 genetic diseases[33]. - The "SMA" test utilizes third-generation sequencing technology for spinal muscular atrophy, providing precise detection of SMN1 and SMN2 gene variations[35]. - The company is committed to the clinical application of genetic sequencing technology, enhancing its service offerings to hospitals and research institutions[31]. - The company aims to expand its market presence through innovative product offerings and strategic partnerships in the healthcare sector[31]. - Huirui Gene launched the world's first clinical liver cancer early screening product "Laisining," validated by a prospective cohort study of over 10,000 people[36]. - Huirui Gene's multi-cancer early screening product "Quansining" can screen for six major high-risk cancers in China, utilizing cfDNA multi-dimensional whole genome sequencing technology[36]. - The company has established a comprehensive product system covering genetic susceptibility testing, early screening, companion diagnosis, efficacy evaluation, and prognosis monitoring in the oncology field[36]. - The company offers a wide range of sequencing analysis services using leading gene sequencing platforms, including Illumina NovaSeq6000 and PacBio Sequel, across various research fields[37]. - The company has developed its own EZ-PALO rapid library preparation method for NIPT library reagents, enabling quick and easy library preparation[38]. - The company collaborates with Illumina to provide sequencing reagents that are equivalent in performance, ensuring stability and accuracy[39]. - The company has established dozens of detailed product types in its basic research services, covering various genomic research areas[37]. - The company’s NIPT library reagents are designed for high efficiency and stability, with products available in various formats for different testing needs[39]. Market Strategy and Expansion - The company is focused on expanding its market presence in the oncology and genetic testing sectors through innovative product development and strategic partnerships[36]. - The company is actively expanding its overseas market presence, particularly in the Middle East[51]. - The company signed a cooperation agreement with a Saudi Arabian company to establish a joint venture focused on genetic testing in the reproductive health field[51]. - The company plans to continue expanding its market presence and investing in new technologies[156]. - Future guidance indicates a positive outlook for revenue growth driven by market expansion strategies[156]. - The company plans to enhance its market expansion strategies in the upcoming quarters, focusing on new product development and technological advancements[164]. - The company aims to achieve a revenue growth target of 20% for the second half of 2023, driven by increased demand for its products[171]. - The company is exploring potential mergers and acquisitions to enhance its market presence and drive growth in the coming years[171]. Financial Management and Investments - The company has not made any changes to its contact information or disclosure locations during the reporting period[20][21]. - The company has not engaged in any significant equity or non-equity investments during the reporting period, indicating a focus on existing operations[67][70]. - The company has no significant asset or equity sales reported during the period, maintaining its current asset structure[71][72]. - The company has not made any securities or derivative investments, reflecting a conservative investment strategy[68][69]. - The company has no fundraising activities reported, suggesting stable financial management without external capital influx[70]. - The company has pledged assets to the Industrial and Commercial Bank of China, indicating a secured financing arrangement for its operations[66]. - The company has not distributed cash dividends or bonus shares for the half-year period[83]. - Employee stock ownership plans are in place, with 85 employees participating, representing 0.32% of the company's total equity[85]. - The company has allocated 2.7 million for research and development in the current period, aiming to innovate and improve product offerings[159]. - The company has allocated 9,514 million yuan for special reserves in the first half of 2023, which is a strategic move to strengthen its financial position[164]. Risks and Challenges - The company has acknowledged potential risks in its future operations, which are detailed in the management discussion section[5]. - The company faces risks related to intensified market competition and declining service prices in the gene sequencing industry, which could adversely affect future performance[75]. - There is a risk of technological and product innovation lag, as the company needs to accelerate its R&D efforts to meet evolving customer demands in the precision medicine sector[75]. - The company faces risks related to product quality control, which could impact brand image and market competitiveness if not managed effectively[77]. - The company is experiencing rapid growth in accounts receivable due to business expansion, which may lead to liquidity issues if not managed properly[78]. - The gross profit margin is at risk of decline due to increased market competition and regulatory uncertainties, despite strong R&D capabilities[78]. - The company is exposed to risks from international operations, including potential legal and operational impacts from geopolitical tensions[77]. Compliance and Governance - The company has not faced any environmental penalties during the reporting period and adheres to relevant environmental regulations[88]. - There were no major litigation or arbitration matters during the reporting period[96]. - The company reported no significant related party transactions during the reporting period[97]. - The semi-annual financial report was not audited[94]. - The company has not implemented any new employee incentive measures during the reporting period[86]. - No commitments were unfulfilled by the actual controllers, shareholders, related parties, acquirers, and other parties related to the company during the reporting period[91]. - There were no non-operating fund occupations by controlling shareholders and other related parties during the reporting period[92]. - The company did not have any violations regarding external guarantees during the reporting period[93].

证券代码：000710 证券简称：贝瑞基因 公告编号：2023-041 成都市贝瑞和康基因技术股份有限公司 第十届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第二次会议于 2023 年 8 月 15 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场与通讯会议相结合的方式召开，会议通知已于 2023 年 8 月 12 日以 邮件形式发送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信息。 本次董事会会议应出席董事 7 名，实际出席会议董事 7 名，会议由董事长高扬先 生主持，董事会秘书和证券事务代表列席了会议。会议的召开和表决程序符合有 关法律、行政法规、部门规章、规范性文件和公司章程的规定。 二、审议情况 1、审议通过《2023 年半年度报告全文及摘要》 表决结果：7 票同意，0 票反对，0 票弃权。 董事会认真审阅了《2023 年半年度报告》，认为其内容真实、准确、完整， 不存在任何的虚假记载、误导性陈述或者重大遗漏。 特 ...

2023 年半年度非经营性资金占用及其他关联资金往来 情况汇总表 | | 资金占用方 | 占用方与上市公 | 上市公司核算 | 2023 年期初 | 2023 年半年度占 | 2023 年半年度 | 2023 年半年度 | 2023 年半年度 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | | | | 用累计发生金额 | 占用资金的利息 | 偿还累计发生 | 期末占用资金 | | 占用性质 | | | 名称 | 司的关联关系 | 的会计科目 | 占用资金余额 | | | | | 原因 | | | | | | | | （不含利息） | （如有） | 金额 | 余额 | | | | 控股股东、实际控制人及 | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人 及其附属企业 | | | | | | | | | | 非经 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2023-042 成都市贝瑞和康基因技术股份有限公司 第十届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届监事会 第二次会议于 2023 年 8 月 15 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场与通讯会议相结合的方式召开，会议通知已于 2023 年 8 月 12 日以 邮件形式发送给各位监事，与会的各位监事均已知悉与所议事项相关的必要信息。 本次监事会会议应出席监事 3 名，实际出席会议监事 3 名，会议由监事会主席李 翔东先生主持，董事会秘书和证券事务代表列席了会议。会议的召开和表决程序 符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。 二、审议情况 1、审议通过《2023年半年度报告全文及摘要》 表决结果：3 票同意，0 票反对，0 票弃权。 监事会认真审阅了《2023年半年度报告》，认为其内容真实、准确、完 整，不存在任何的虚假记载、误导性陈述或者重大遗漏。 ...

1、报告期内，公司未发生控股股东及其他关联方占用公司资金的情况，也 不存在以前年度发生并延续到报告期内的占用公司资金的情况。 2、报告期内，公司及控股子公司担保总额为不超过人民币 8 亿元，截至本 报告期末，尚在有效期内的担保总额为不超过 8 亿元（均为上市公司及全资子公 司为全资子公司提供之担保）。上述担保均已履行相应的审议程序，为公司正常 经营所需，除上述对外担保外，上市公司及控股子公司不存在其他对外担保，不 存在对合并报表外单位提供担保的情况，亦不存在涉及债务逾期、诉讼的担保及 因被判决而应承担责任的担保。 独立董事：李耀、张大可、胡诗阳 成都市贝瑞和康基因技术股份有限公司独立董事 独立董事关于公司控股股东及其他关联方占用公司资金、公司 对外担保情况的专项说明和独立意见 根据《中华人民共和国公司法》、《深圳证券交易所股票上市规则》、《关于在 上市公司建立独立董事制度的指导意见》等法律、法规和规范性文件以及《成都 市贝瑞和康基因技术股份有限公司章程》、《独立董事制度》等有关规定，我们作 为成都市贝瑞和康基因技术股份有限公司（以下简称"公司"、"上市公司"）的 独立董事，对公司控股股东及其他关联方占用公司资 ...

Financial Performance - The company's revenue for Q1 2023 was ¥280,207,812.40, a decrease of 10.62% compared to ¥313,494,177.23 in the same period last year[5] - The net loss attributable to shareholders was ¥20,738,437.15, representing a 73.86% increase from a loss of ¥11,928,399.03 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.06, a decline of 50.00% from -¥0.04 in the same period last year[5] - Net loss for Q1 2023 was CNY 20,110,444.46, compared to a net loss of CNY 12,217,400.42 in Q1 2022, indicating a worsening of 64.5%[18] - The company reported a total comprehensive loss of CNY 22,543,430.36 for Q1 2023, compared to a loss of CNY 13,266,230.07 in Q1 2022[18] Cash Flow - The net cash flow from operating activities improved by 17.68%, amounting to -¥41,528,166.03 compared to -¥50,449,164.21 in the prior year[5] - The company's cash flow from operating activities was CNY 292,298,259.97 in Q1 2023, down from CNY 382,947,930.27 in Q1 2022, representing a decline of 23.6%[20] - The net cash flow from financing activities was -¥7,632,206.64, compared to -¥94,916.69 in Q1 2022, showing a significant deterioration[22] - The total cash outflow from operating activities was 337,608,941.20, compared to 435,891,737.57 in Q1 2022, indicating a reduction of about 22.5%[21] - Total cash inflow from investment activities was 6,484,002.22, while cash outflow was 2,001,375.48, resulting in a net cash flow of 4,482,626.74, compared to -26,194,475.14 in the same period last year[21] Assets and Liabilities - Total assets as of March 31, 2023, were ¥3,170,793,442.57, a decrease of 0.94% from ¥3,200,862,871.74 at the end of the previous year[5] - The total liabilities as of Q1 2023 were CNY 864,689,294.83, slightly down from CNY 871,535,028.84 in the previous quarter[18] - The total equity attributable to shareholders decreased by 1.04% to ¥2,277,535,038.01 from ¥2,301,386,725.87 at the end of the previous year[5] - The company's long-term equity investments decreased to CNY 104,727,156.18 from CNY 112,536,596.20, a decline of approximately 7%[14] Operational Efficiency - Total operating costs for Q1 2023 were CNY 282,899,819.60, down from CNY 309,299,721.50 in the previous year, reflecting a reduction of 8.5%[17] - Research and development expenses decreased to CNY 20,680,673.90 in Q1 2023 from CNY 26,127,459.15 in Q1 2022, a reduction of 21.0%[17] - The company experienced a 35.10% decrease in prepayments, which fell to ¥22,284,411.38 from ¥34,338,731.67[8] Income and Other Financial Metrics - Other income decreased by 37.10%, totaling ¥1,412,798.46 compared to ¥2,246,212.02 in the same period last year[8] - The company reported a significant increase in credit impairment losses, which rose by 157.90% to -¥6,670,255.61 from -¥2,586,347.73 in the previous year[8] - The company received tax refunds amounting to 231,446.97, compared to 23,868.88 in the previous year, marking a substantial increase[21] - The company paid 16,170,026.56 in taxes, down from 22,336,177.06 in Q1 2022, reflecting a decrease of approximately 27.6%[21] Strategic Focus - The report indicates a strategic focus on maintaining liquidity while managing receivables and inventory levels effectively[13] - The company is actively managing its financial assets, with trading financial assets remaining stable at CNY 4,505,243.01[14]

Business Focus and Strategy - Berry Genomics reported a significant shift in its main business focus from automotive parts to high-throughput sequencing-based genetic testing services and equipment sales following a major asset restructuring completed in August 2017[22]. - The company aims to expand its market presence, leveraging advancements in non-invasive prenatal testing and other genetic testing technologies[5]. - The company is positioned within a key emerging industry, as highlighted in the "14th Five-Year Plan" which emphasizes health technology and biotechnological advancements[34]. - The company aims to become a gene technology firm focused on clinical commercialization and health big data development, leveraging existing testing platforms to accumulate genetic data[98]. - The company plans to enhance its existing non-invasive products and services to assist clinical decision-making in precision medicine[99]. Financial Performance - The company's operating revenue for 2022 was ¥1,368,007,211.88, a decrease of 3.81% compared to ¥1,422,180,921.29 in 2021[24]. - The net profit attributable to shareholders was -¥254,778,590.81, representing a decline of 129.91% from -¥110,818,562.80 in the previous year[24]. - The cash flow from operating activities was ¥21,178,809.92, down 77.48% from ¥94,031,452.65 in 2021[24]. - The basic and diluted earnings per share were both -¥0.82, a decrease of 164.52% compared to -¥0.31 in 2021[24]. - The company reported a total revenue of 1,055.04 million CNY, representing a 2.25% increase compared to the previous year[172]. Research and Development - The company has committed to ongoing research and development in new products and technologies to enhance its service offerings in genetic testing[5]. - The company is actively involved in the development of new technologies and products, including third-generation sequencing techniques for various genetic disorders, enhancing diagnostic accuracy[40]. - The company has developed over 1 PB of gene data annually, enhancing its capabilities in clinical information interpretation and artificial intelligence algorithms[54]. - The company has established a robust research service platform utilizing leading sequencing technologies, including Illumina NovaSeq6000 and PacBio Sequel, to support various scientific research fields[43]. Market Trends and Opportunities - The gene sequencing industry is rapidly growing, supported by national policies and increasing public awareness of disease prevention[34]. - The high-throughput sequencing market is expected to continue rapid growth, driven by decreasing sequencing costs and increasing application scenarios in reproductive health, oncology, and consumer-grade genetic testing[37]. - The Beijing Medical Insurance Bureau included 16 assisted reproductive technologies, such as artificial insemination and embryo transfer, in the Class A reimbursement scope, which is expected to enhance the penetration of gene sequencing products and services[37]. Corporate Governance and Management - The company operates independently from its controlling shareholders, ensuring no overlap in business operations or financial dealings[111]. - The company has established a complete independent financial system, with separate financial management and decision-making processes, ensuring no interference from shareholders[113]. - The company has a robust organizational structure with clearly defined responsibilities, operating independently from its major shareholders[113]. - The company has conducted multiple shareholder meetings, with participation rates of 32.44% and 19.60% in the respective meetings held in 2022[114]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,438, with 1,434 in major subsidiaries[137]. - The educational background of employees includes 21 with PhDs, 309 with master's degrees, and 724 with bachelor's degrees, reflecting a highly educated workforce[137]. - The company has established a competitive salary system to align with business development and market standards, integrating performance management with salary incentives[138]. - The company has a detailed regulation on related party transactions, ensuring strict compliance and risk control[146]. Risks and Challenges - Future operational risks and challenges are outlined in the management discussion, emphasizing the need for investor awareness regarding potential uncertainties[5]. - The company faces risks from industry policy changes, intensified market competition, and potential declines in service prices[101]. - The rapid expansion of accounts receivable poses a risk of bad debts, which could impact the company's operational development[104]. - The company is exposed to financial risks, including potential declines in gross margin due to market competition and regulatory uncertainties[104]. Product and Service Offerings - The company focuses on gene detection services based on high-throughput sequencing technology, targeting areas such as reproductive health, genetic disease detection, and tumor detection[38]. - The company provides comprehensive genetic testing services covering three levels of birth defect prevention, including carrier screening for 153 diseases and pre-implantation genetic testing[39]. - The company offers non-invasive prenatal testing (NIPT) for chromosomal aneuploidy screening and a more advanced NIPT Plus for 100 chromosomal and genomic diseases[39]. - The company has developed a comprehensive cancer screening product "Laisining" for liver cancer, validated by a prospective cohort study involving over 10,000 participants, and included in the national early screening strategy[42]. Shareholder and Equity Information - The company reported a total shareholding of 58.45 million shares at the end of the reporting period, down from 64.11 million shares at the beginning, indicating a decrease of approximately 8.3%[117]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 12.41% of the shares, totaling 44,002,000 shares, with no changes during the reporting period[199]. - The total number of shareholders at the end of the reporting period was 41,358, with a slight decrease from the previous month[198]. - The company has maintained a consistent shareholder base without any significant changes in ownership during the reporting period[200].

Group 1: Restructuring Overview - The restructuring is led by the actual controller, with the project being selected after thorough comparison [2] - The actual controller has a dedicated team for related projects [2] - The restructuring aims to develop a dual-main business model, contingent on the future development of both business segments [3] Group 2: Old Ken Medical's Operations - Old Ken Medical withdrew its IPO application in May 2013 due to market changes and strategic needs [3] - The company is collaborating with the UK New Helix Group to establish a nationwide medical disinfection service outsourcing system [3] - The business performance of Old Ken Medical in January and February of this year has been reported as good [4] Group 3: Management and Financing Post-Reorganization - Post-reorganization, Liu Xia is proposed to be nominated as a candidate for the board of directors and to serve as the deputy general manager of Tianxing Instrument [4] - Daily operations of Old Ken Medical will primarily be managed by its own team, with Tianxing Instrument appointing directors and financial leaders [4] - Financing will mainly support Old Ken Medical, while Tianxing Instrument's significant expenditures will be related to relocation and new factory construction [4] Group 4: Risks and Future Plans - The reorganization faces risks such as regulatory approval, integration challenges, and inherent risks of Old Ken Medical [4][5] - The timeline for completing the reorganization is uncertain and depends on the China Securities Regulatory Commission's review [4][5]